Sen. Maggie Hassan questions Trump administration over mystery weight loss drug patient

[BumRushDaShow]

Source: MS NOW News

Jun. 24, 2026, 7:30 PM EDT


Sen. Maggie Hassan, D-N.H., on Wednesday questioned the Trump administration over the mystery individual who got exclusive access to a new weight loss drug that is not available to the general public. Hassan penned a letter to Health and Human Services Secretary Robert F. Kennedy Jr. expressing concern over reports that a “well-connected individual,” whom she suggested is President Donald Trump, received special, free access to the experimental weight loss drug retatrutide.

The New Hampshire Democrat shared the letter with MS NOW in an exclusive interview with “The Weeknight.” “We’ve got somebody highly connected in this administration who’s making special deals for one person and it just speaks to the whole way this administration operates,” Hassan told MS NOW. “They’re thinking about the highly connected, the wealthy.”

In her letter to Kennedy, the congresswoman said she was concerned that the administration was “bending the rules” by giving an individual special access to the drug through the Food and Drug Administration. “I am deeply concerned by new reporting that suggests you may be bending the rules of a federal program, and exerting improper political pressure, in order to provide a well-connected individual with free access to an exclusive prescription drug,” the senator wrote to Kennedy.

Hassan’s letter comes a day after Stat News reported that drug manufacturer Eli Lilly and the Food and Drug Administration allowed special access to retatrutide for a lone 79-year-old man in April through its “compassionate use” program.

Read more: https://www.ms.now/news/maggie-hassan-retatrutide-patient-white-house

---

Link to Sen. Hassan PRESS RELEASE - Senator Hassan Presses for Answers After Reports That Trump May Have Received Special, Free Access to Medication as Prescription Costs Soar

Link to LETTER (inquiry) (PDF) - https://www.hassan.senate.gov/imo/media/doc/624.26lettertorfkjr.pdf

[Scrivener7]

1. "Compassionate use" means the patient is terminal

and the experimental drug might help. That seems unlikely for a weight loss drug.

But the drug is also good for "cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease (MASLD)" https://www.lilly.com/news/stories/what-to-know-about-retatrutide

But there are other approved drugs for those conditions...

Something is weird here. Either that or he's just scamming again.

But I bet it is Cankles.

[tanyev]

4. Ain't no other 79 year old this administration would make special deals for.

🤨

[snowybirdie]

2. But he looks

Fatter than ever! Doesn't work

[Orrex]

5. Maybe he's taking them as suppositories rather than orally

and they're working in reverse?

[wolfie001]

3. ........

[Scrivener7]

7. Jump scare.

[wolfie001]

8. As intended

[travelingthrulife]

6. He rapes kids. Is this really important?

[Scrivener7]

9. If the "compassionate use" means he's dying, I want to know. But yeah. And we have a war

and an economy ready to implode, and the most corrupt government that we have ever had and the possibility of a takeover of our elections by bad actors and, and, and.

So yeah. I hear you.

[amcgrath]

10. The question I'd like answered,

If it is Trump, is why protocols have been lifted to give an experimental anti- obesity drug to a man whose repeated medical reports and declarations state that he is not obese.
An inquiry should include an independent measuring of both his height and weight. Whether they choose to follow that up with questions about falsifying medical reports is up to congress. - apart from false declarations to a government which is charged with monitoring a presidents health (25th) it also raises questions of whether Trump has been benefiting from a state paid health insurance program in which the insurer has been lied to? That would mean fraud by Trump and his attending physicians. And we know where Trump stands on the wrongful claims on state benefits